Dr. Muhamed Baljevic completed his medical education at Weill Cornell Medical College, his internship/residency at New York-Presbyterian Hospital, his hematology/medical oncology training at The University of Texas MD Anderson Cancer Center, and pursued his master’s in clinical and translational research at The University of Texas Graduate School of Biomedical Sciences. He is Assistant Professor at the University of Nebraska Medical Center where he also works as a plasma cell dyscrasia specialist, transplanter, and clinical/translational trialist at Fred & Pamela Buffet Cancer Center (FPBCC).

Dr. Baljevic is a member of the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the European Hematology Association. He serves on the editorial board for Frontiers in Oncology and has contributed to numerous publications and several book chapters.

At FPBCC, Dr. Baljevic investigates early-phase development of pre-clinical concepts in post-transplant immune reconstitution. His research seeks to identify novel approaches for treatment of B-cell and myeloid malignancies.